OV-866 (2) cell line

Cat. #161767

OV-866 (2) cell line

Cat. #: 161767

Organism: Human

Tissue: Derived from ascites


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Inventor: Anne-Marie Mes-Masson and Diane Provencher

Institute: Centre Hospitalier de L’université de Montréal

Primary Citation: Fleury et al. 2015. Genes & Cancer. 6(9-10):378-398. PMID: 26622941

Tool Details

Tool Details


  • Name: OV-866 (2) cell line
  • Alternate name: OV-866 (2)
  • Organism: Human
  • Gender: Female
  • Tissue: Derived from ascites
  • Donor: Age of diagnosis:60; BRCCA hereditary status: negative; Grade 2 – Stage IIIC; Mutations: TP53; Carboplatin/Taxol
  • Morphology: Predominantly small epithelial type cells, often aggregated, and fibroblast shaped cells notably absent. Formed loose compat spheroids with irregular margins
  • Growth properties: Adherent
  • Crispr: No
  • Receptors of note: No
  • Description: Epithelial ovarian cancer cell lines spontaneously derived from high-grade serous ascites of patients with recurring disease and who had been treated with chemotherapy prior to collection. The '2' after OV866(2) refers to the fact that this cell line was established from a second ascites sample from the patient
  • Production details: Patient ascites were centrifuged and seeded in 100mm plate with OSE medium and maintained for 40 days with weekly media replacement.
  • Additional notes: Taken from female who was age 60 at diagnosis, BRCA hereditary was negative, disease stage was IIIC. No prioir personal history of cancer or prioir oncologic treatment, and was not chemotherapy naive at the time of sample collection


  • Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
  • Atmosphere: Low oxygen conditions of 7% O2 and 5% CO2
  • Cultured in antibiotics: Amphotericin B and Gentamicin


  • Vias et al. 2023. Elife. 11
  • 12:e83867. PMID: 37166279 Sevinyan et al. 2022. Cancers (Basel). 16
  • 14(22):5628. PMID: 36428724 Asare-Werehene et al. 2023. Cancers (Basel). 30
  • 15(9):2566. PMID: 37174032